Data suggest that MIR137 regulates cell proliferation via expression of CDC42 (cell division cycle protein 42) and CDK6 (cyclin-dependent kinase 6); expression of MIR137 in lung cancer cells downregulates CDC42/CDK6 and induces G1 cell cycle arrest.

Our data provided evidence that miR-137 was closely related to multi-drug resistance of small cell lung cancer

microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18

miR-137 downregulation was related to its promoter hypermethylation in lung cancer.

miR-137/BMP7 axis could contribute to the progression of non-small cell lung cancer.

Results showed the mechanism in which miR-137 regulates the expression of DCLK1, and demonstrated the opposite expression patterns of miR-137/DCLK1 in human non-small cell lung carcinoma and colon cancer stem cells.

Low miR137 expression is associated with drug resistance in lung cancer.

miR137 underexpression is associated with non-small cell lung cancer.

miR-137 is a Slug-induced miRNA that relays the pro-metastatic effects of Slug by targeting TFAP2C in non-small cell lung cancer cells.

XIST positively regulated PXN levels by sponging miR-137 in vitro and in vivo. Collectively, our study provided the evidence for the cross-talk between XIST, miR-137, and PXN, shedding light on the therapy for non-small cell lung cancer .